EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Mechanistic and therapeutic perspectives of miRNA-PTEN signaling axis in cancer therapy resistance

Di Wu, Chunjie Huang, Kaifeng Guan

Biochemical Pharmacology · 2024

DOI: 10.1016/j.bcp.2024.116406 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2024. Verfasst von Di Wu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Reproductive Medicine, School of Medicine, Nantong University, Nantong 226001, China. Hauptthemen laut MEDLINE: PTEN Phosphohydrolase, MicroRNAs, Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 152 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer, being one of the most lethal illnesses, presents an escalating clinical dilemma on a global scale. Despite significant efforts and advancements in cancer treatment over recent decades, the persistent challenge of resistance to traditional chemotherapeutic agents and/or emerging targeted drugs remains a prominent issue in the field of cancer therapies. Among the frequently inactivated tumor suppressor genes in cancer, phosphatase and Tensin Homolog (PTEN) stands out, and its decreased expression may contribute to the emergence of therapeutic resistance. MicroRNAs (miRNAs), characterized by their short length of 22 nucleotides, exert regulatory control over target mRNA expression by binding to complementary sequences. Recent findings indicate that microRNAs play varied regulatory roles, encompassing promotion, suppression, and dual functions on PTEN, and their aberration is implicated in heightened resistance to anticancer therapies. Significantly, recent research has revealed that competitive endogenous RNAs (ceRNAs) play a pivotal role in influencing PTEN expression, and the regulatory network involving circRNA/lncRNA-miRNA-PTEN is intricately linked to resistance in various cancer types to anticancer therapies. Finally, our findings showcase that diverse approaches, such as herbal medicine, small molecule inhibitors, low-intensity ultrasound, and engineered exosomes, can effectively overcome drug resistance in cancer by modulating the miRNA-PTEN axis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PTEN PhosphohydrolaseMicroRNAsNeoplasmsDrug Resistance, NeoplasmSignal TransductionAntineoplastic AgentsHumansAnimalsGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

Cancer therapyChemoresistanceExosomeHerbal medicinePTENmiRNAs

Substanzen

PTEN PhosphohydrolaseMicroRNAsPTEN protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Institute of Reproductive Medicine, School of Medicine, Nantong University, Nantong 226001, China.
  • Institute of Reproductive Medicine, School of Medicine, Nantong University, Nantong 226001, China. Electronic address: goodlife.huang@ntu.edu.cn.
  • School of Advanced Agricultural Sciences, Peking University, Beijing 100871, China. Electronic address: guankaifeng1121@pku.edu.cn.

Zitieren

APA

Wu, D., Huang, C., & Guan, K. (2024). Mechanistic and therapeutic perspectives of miRNA-PTEN signaling axis in cancer therapy resistance. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2024.116406

Vancouver

Wu D, Huang C, Guan K. Mechanistic and therapeutic perspectives of miRNA-PTEN signaling axis in cancer therapy resistance. Biochemical Pharmacology. 2024. doi:10.1016/j.bcp.2024.116406

BibTeX
@article{Wu2024,
  author = {Wu, Di and Huang, Chunjie and Guan, Kaifeng},
  title = {Mechanistic and therapeutic perspectives of miRNA-PTEN signaling axis in cancer therapy resistance},
  journal = {Biochemical Pharmacology},
  year = {2024},
  doi = {10.1016/j.bcp.2024.116406}
}
Kostenlos starten →